Background. The P-myosin heavy chain (P-MHC) gene has been identified as a major locus for familial hypertrophic cardiomyopathy (FHCM). We recently showed that one of the common mutations associated with FHCM is expressed in the cardiac muscle messenger RNA (mRNA) of an affected individual. Since -MHC is a major sarcomeric protein of cardiac and skeletal muscle, studies were performed to determine whether the mutation is also expressed in skeletal muscle.
H ypertrophic cardiomyopathy (HCM) is the first inherited primary cardiomyopathy for which the chromosomal locus has been mapped and the putative gene isolated.1-3 The implications are obvious considering that HCM is the most common cause of sudden death in the young, particularly in athletes.4.5 Unraveling how mutations in 3-myosin heavy chain (j3-MHC) (putative gene) provides the molecular basis for HCM has other important implications since HCM provides a paradigm for understanding the molecular basis of clinical and morphological manifestations com-mon to many other cardiac diseases, i.e., dyspnea, syncope, angina, cardiac failure, and ventricular hypertrophy. Current genetic linkage studies performed in families with HCM suggest that the p-MHC gene, which is located on the long arm of chromosome 14,6 is a major locus for this disease.1-3 Several mutations in the p-MHC gene in families with HCM have been identified, and their cosegregation with the disease in affected individuals strongly indicates that they are responsible for the disease. [7] [8] [9] Establishment of a causal relation between the putative mutant gene and the pathogenesis of the disease often requires several years of investigation. Despite the compelling evidence that mutations in the f3-MHC gene are responsible for HCM in families linked to chromosome 14, there remains intriguie if not concern as to how these mutations can lead to the pathogenesis of familial HCM (FHCM). The f3-MHC protein, a major sarcomeric contractile molecule, makes up 35% of the cardiac myocyte protein in both the left and right ventricles.10 In addition, 3-MHC protein is a major myosin in skeletal muscle. [11] [12] [13] It is perplexing that despite ubiquitous distribution of the j3-MHC protein, the hypertro-phy in FHCM is localized to the left ventricle and primarily the interventricular septum. 14 The most common mutation reported for FHCM in the j-MHC gene appears to be that of the missense mutation in exon 13 whereby an adenine substitutes for a guanine in position 1208 of the coding sequence7'8"5 and is associated with high incidence of sudden death.9'16 We recently identified a family with FHCM with this mutation, obtained an endomyocardial biopsy of the right ventricle from the proband, and showed that the 3-MHC missense mutation in exon 13 of the f3-MHC gene is expressed in the messenger RNA (mRNA) of the myocardium.17 Since p8-MHC is known to be a major myosin of skeletal muscle, a biopsy was obtained from the biceps muscle of the same proband and studies were performed to determine whether the mutation is expressed in the 13-MHC mRNA. With the polymerase chain reaction (PCR), analogous to studies performed on cardiac muscle,17 exon 13 of the f3-MHC was amplified from the mRNA of the skeletal muscle. A similar approach was used to amplify the mRNA extracted from lymphocytes of the proband. Simultaneous analysis of the DNA from the proband showed the exon 13 missense mutation was present as previously reported. Our results show the mutation is expressed in the mRNA of lymphocytes and skeletal muscle.
Methods A family with FHCM from southwest United States was identified, and a pedigree was established. After an informed consent was obtained, each family member was screened by history, physical examination, ECG, and two-dimensional echocardiography. In addition, blood was collected from each family member for DNA extraction.
Diagnostic Criteria for HCM Diagnosis of HCM was made by echocardiographic criteria defined as the presence of septal or ventricular hypertrophy of .13 mm in the absence of other potential causes of hypertrophy such as hypertension or valvular disease.
Skeletal Muscle Biopsy
Informed consents were obtained from the proband and a normal individual (control). A skeletal muscle (biceps brachii) biopsy was obtained from both the proband and the normal individual. The samples were immediately frozen in liquid nitrogen for subsequent use. Isolation of DNA Blood was collected from all members of the family, and DNA was extracted from the blood using an Applied Biosystem (Foster City, Calif.) nucleic acid extractor. In addition, lymphoblastoid cell lines were established for family members by Epstein-Barr virus transformation16 for a renewable source of genomic DNA.
Amplification of DNA by Polymerase Chain Reaction
The methods used for PCR amplification of DNA were published previously.17 In brief, based on the published sequence of the p-MHC gene,18"9 a set of primers were designed to amplify exon 13 of this gene. The sequence of the sense primer (5'CTCTTACCAA-CTTTGCTCTTGC3') was identical to the sequence of intron 12 and that of the antisense primer (5'CTGC-TGGACATTCTGCCCCTTGG3') complementary to the sequence of the 3' end of exon 13 of the ,B-MHC gene. The primers were designed to amplify a segment 154 base-pairs (bp) long. The PCR reaction mix contained 250 ng DNA as the template, 0.2 ,uM of each primer, 200 ,uM 4-dNTP, 1 unit Thermus equaticus DNA polymerase (Pharmacia, 5,000 units/mL), 10 mM Tris-HCl (pH 8.3, at room temperature), 50 mM KCl, 0.001% (wtlvol) gelatin, and 1.5 mM MgCl2. The DNA initially was denatured by exposing it to 95°C for 3 minutes and then was amplified for 30 cycles in a Perkin Elmer Cetus DNA thermal cycler. Each cycle consisted of denaturing at 94°C for 1 minute, annealing at 57°C for 30 seconds, and extension at 72°C for 30 seconds.
The PCR products were separated by electrophoresis on 2% agarose gel and identified after ethidium bromide staining by ultraviolet light illumination. The 154-bp product was excised from the gel and extracted using Sephaglas BandPrep Kit (Pharmacia). The purified product was digested with restriction endonuclease Ddel (48 units) at 37°C for 2 hours. The digestion products were separated by electrophoresis on 3% agarose gel and visualized by ultraviolet light illumination after staining by ethidium bromide.
Tissue RNA Extraction
Total RNA was extracted from skeletal muscle and lymphocytes by RNAzol method (Cinna/Biotecx Laboratories, Houston, Tex.) as previously reported. 17 The total RNA extracted was approximately 400 jig from 100 mg of skeletal muscle and 250 ,ug from 2X 106 lymphocytes.
Reverse Transcription and First-Strand Complementary DNA Synthesis
Reverse transcription was performed for first-strand complementary DNA (cDNA) synthesis using 1 ,ug extracted from skeletal muscle of total RNA and 1 jig extracted from lymphocyte of total RNA as templates. We designed an antisense primer with a sequence complementary to the sequence of exon 16 (5'ATCAT-CGATGTCCCTTTTGAGCTCTGAGCACTCAT-CTTCC3') of the 13-MHC gene. The reverse transcription reaction was performed as follows: 2 ,uL of reverse transcription buffer {[5 x reverse transcription buffer: 250 mM Tris-HCl (pH 8.3 at room temperature), 375 mM KCl, 15 mM MgCl1], GIBCO BRL, Gaithersburg, Md.} and 1.5 ,uL of 10 ,uM antisense primer to exon 16 were added to total RNA, and the reaction volume was corrected to 10 ,L by adding sterile diethyl pyrocarbonate deionized water. The reaction was denatured for 5 minutes at 85°C. To this reaction, 1 ,L of reverse transcription buffer, 1 ) were added in a total volume of 15 ,Lp to synthesize the first-strand cDNA. The final concentration of antisense primer and 4-dNTP in the reaction was 1 ,uM and 1 mM, respectively. The reaction was incubated at 42°C for 2 hours and terminated by heat inactivation (68°C for 20 minutes).
Reverse Transcription-Polymerase Chain Reaction
A new set of primers was designed to encompass exon 13. The sequence of the sense primer (5'GAGGATC-CCTCCATGTATAAGCTGACAGG3') was identical to the sequence of exon 12, and the sequence of the antisense primer (5'TTAAGCTTTCTCCAGGGTG-GCATTGATGCG3') was complementary to the sequence of exon 14 of the f3-MHC gene. The primers were designed to amplify a fragment of cDNA of 321 bp. A BamHI restriction site was incorporated at the 5' end of the sense primer, and a HindIII restriction site was incorporated at the 5' end of the antisense primer. These two restriction sites were not present in the segment amplified by PCR. PCR was performed as follows: The reverse transcription product was diluted fourfold with 1 xPCR buffer [50 mM KCl, 10 mM Tris-HCl (pH 9.0 at 25'C), 1 The amount of reverse transcription-polymerase chain reaction products obtained from the skeletal muscle sample was adequate without further amplification. However, the reverse transcription-polymerase chain reaction product amplified from the lymphocytes after 35 cycles required an additional 40 cycles of amplification (total of 75 cycles) to yield adequate amount of product for subsequent digestion with Ddel restriction endonuclease. Initial reverse transcriptionpolymerase chain reaction product was diluted with sterile H20 and used as template for reamplification under reaction conditions as described above.
Separation and Extraction of Reverse

Transcription-Polymerase Chain Reaction Products
Reverse transcription-polymerase chain reaction products were separated by electrophoresis using 2.5% low melting point agarose. The 321-bp reverse transcription-polymerase chain reaction product was excised from the gel under ultraviolet illumination and extracted from the gel using Sephaglas BandPrep Kit (Pharmacia).
Ddel Digestion, Radiolabeling, and Electrophoresis of the Ddel Digestion Products
The extracted reverse transcription-polymerase chain reaction products were digested with restriction endonuclease Ddel (48 units) in a total volume of 60 ML at 37°C for 2 hours. The digestion products were labeled with 32P at the 5' end using standard methodology.20
The final reaction condition contained 50 mM Tris-HCl (pH 7.6), 10 mM MgCl2, 15 mM DTT, and 10 units polynucleotide kinase (Pharmacia) in a total reaction volume of 30 ML. The reaction was incubated at 37°C for 45 minutes and then terminated by heat inactivation of polynucleotide kinase at 65°C for 10 minutes. The labeled products were ethanol precipitated, lyophilized, and suspended in sterile deionized water. An aliquot was loaded on to a 6% polyacrylamide gel and electrophoresed for 75 minutes. Subsequently, the gel was dried and exposed to irradiation film.
Results
The family studied was a small white family residing in southwest United States; it was composed of 15 individuals (including spouses). Six are affected with FHCM, of whom four are alive. The other two affected individuals died at ages 32 and 58 years. Four of the six affected individuals had septal hypertrophy and two had concentric left ventricular hypertrophy. Three had left ventricular outflow tract obstruction, of whom two required myomectomy for relief of symptoms. One individual died suddenly, and one died from recurrent cerebrovascular disease (presumably embolic). Although four of the affected individuals had severe disease, two affected individuals were only mildly symptomatic.
DNA Results
DNA from all members of the family and from a normal individual (control) was amplified in the region of exon 13 between nucleotides 8744 and 8897 of the p8-MHC gene by PCR. Electrophoresis of the PCR products showed the expected 154-bp product in all individuals, including the proband. Ddel digestion of the product from the unaffected individuals and the control showed two fragments of 70 and 84 bp. In contrast, Ddel digestion of the 154-bp product from the proband and affected individuals showed four fragments of 84, 70, 52, and 32 bp (Figure 1 ). This indicates that the proband has both the normal and mutant alleles. In the mutant allele, substitution of an adenine for guanine creates an additional Ddel site. The normal allele with only one Ddel restriction site showed two fragments (70 and 84 bp), whereas the mutant allele containing two Ddel restriction sites, the second site being in the 84-bp fragment, yielded three fragments (70, 52, and 32 bp). The DNA from all affected individuals in this family showed four fragments on Ddel digestion, indicating they inherited the mutation, whereas all unaffected individuals, except for one member who is only 10 years old, showed only two fragments. Thus, the disease and the mutation cosegregate in keeping with a mendelian inheritance pattern.
Reverse Transcription-Polymerase Chain Reaction Results
High-purity RNA was extracted from a skeletal muscle biopsy and from lymphocytes. Agarose gel electrophoresis performed on the PCR products from the normal and the proband (skeletal muscle and lymphocytes) showed a 321-bp product, as expected. After excision from the gel, a portion of the purified product was digested with Ddel restriction endonuclease, 5' end-labeled with 32P, and electrophoresed on acrylamide gels (Figure 2 ). The digested reverse transcriptionpolymerase chain reaction product from the normal individual showed two restriction fragments of 140 and 181 bp, as expected with a single Ddel restriction site. In contrast, reverse transcription-polymerase chain reac- . In lane 6, Ddel digestion fragments of the PCR product (exon 13 DNA) of the proband (containing amplified DNA from normal and mutant alleles) is shown. There are fourfragments of84, 70, 52, and 32 bp. Notice that the 70-bp band is denser than the 84-bp band, despite its smaller size, as halfof the 84-bp product amplified from the mutant allele (exon 13) DNA contained a Ddel restriction site due to a point mutation and, therefore, was digested into two fragments of 52 and 32 bp. Digestion of the PCR product from a normal individual showed only two fragments of 84 and 70 bp, as expected (lane 7). tion product from the proband produced four fragments of 181, 140, 149, and 32 bp. This indicates that both normal and mutant alleles have been amplified, the latter having a second Ddel restriction site, and on digestion cleaves into three fragments of 149, 140, and 32 bp, whereas the normal allele gives just two fragments (181 and 140 bp).
Cloning and Sequencing of Normal and Mutant Alleles
The 321-bp reverse transcription-polymerase chain reaction product from the proband template contained amplified products from the normal and mutant alleles. Therefore, a plasmid library was made, and clones containing the normal and the mutant reverse transcription-polymerase chain reaction products were identified by Ddel digestion. Ddel digestion of the insert from the normal clone showed two fragments of 181 and 140 bp, whereas Ddel digestion of the insert from the mutant clone showed three fragments of 149, 140, and 32 bp. The mutant recombinant DNA was sequenced, and the sequence analysis showed that in position 1208 of the coding sequence, an adenine had substituted for a guanine, thereby creating a new Ddel restriction site (CTNAG) in this position.
Discussion In this study of a family with FHCM, we showed the mutation to be that of a missense in exon 13 of the f3-MHC gene (G-IA) that was present in affected individuals but none of the controls. This inheritance, as expected, is autosomal dominant, and the mutation cosegregates with the disease. The penetrance is very high since only one individual has inherited the genetic defect without manifesting the disease. Since this individual is only 10 years old and penetrance is age dependent, it is highly likely that he will develop the phenotype later in life. mRNA extracted from a biopsy of the proband after being reversely transcribed, amplified, and analyzed showed two alleles-one normal and one mutated alleleindicating that the mutation is expressed at the mRNA level. Although it was expected, it is the first documentation that a mutation in the ,8-MHC of a patient affected with FHCM is expressed in the mRNA of skeletal muscle. The cardiac MHC proteins are the products of genes a and ,B located adjacent to each other on chromosome 14 and separated by only about 3.6 kbp.21 The MHC protein is a dimer of either 2 a-or 18-subunits or a combination of a and 1. 3-MHC (,/1,8) is the predomi-nant myosin in right and left ventricular myocardia (95-100%) with a-MHC, although predominant in the atria, only minimally expressed in the ventricles. 12, [22] [23] [24] Unlike cardiac, skeletal muscle is comprised of two types of muscle fibers -type I (slow twitching) and type II (fast twitching). In most human skeletal muscles, the fiber composition is such that usually one type predominates slightly over the other; however, with few exceptions, type I comprises 40-60% of all skeletal muscle.25 f3-MHC is the predominant myosin of type I fibers. [12] [13] [14] Thus, although 3-MHC is not the exclusive myosin in skeletal muscle as it is in ventricular myocardium, it is a major contractile protein of all skeletal muscles, and in muscles rich in type I fibers it is the predominant myosin. In a study of 36 human muscles, type I (fB-MHC major myosin) fibers varied from 38% to -70% of the total muscle.25 Thus, it is not surprising that the missense mutation in the P3-MHC gene is expressed in the mRNA in skeletal muscle as well as in cardiac muscle in our proband with FHCM. However, it is surprising that despite the mutation being expressed, skeletal muscle appears to exhibit normal function. This is perhaps no more surprising than the finding of no disease in the right cardiac ventricle given j3-MHC is the predominant myosin (95-100%) as it is in the left ventricle. The finding of the disease only in the left ventricle and primarily the septum, despite expression in both ventricles and in human skeletal muscle, strongly suggests that the abnormality is due in part to an interaction with the local environment. A major difference between the left and right ventricles is, of course, that the left ventricle is a high-pressure chamber and responds routinely to a high-pressure afterload compared with the right ventricle, which is predominantly a volume chamber. The development of hypertrophy in response to the environment also is in keeping with the observation that the disease does not become manifest until later in life. In one study, it was observed that affected children of parents with FHCM showed no cardiac hypertrophy at the age of 11 years, whereas by the age of 16 years they had developed significant ventricular septal hypertrophy. 26 There are a few reports on patients with FHCM in which there were abnormalities in the electromyogram of skeletal muscle.27-29 These findings, however, may be nonspecific since similar findings have been reported in patients with cardiac failure without hypertrophic cardiomyopathy.29 It is, however, of some interest that in the patients with FHCM, the abnormality in skeletal muscle was primarily in type I fibers, which contain predominantly j-MHC and would be the fibers in which the mutation would be expressed. It is intriguing and somewhat perplexing that a mutation expressed in 3-MHC mRNA, the major myosin and protein of both right and left ventricles should be manifested as a disease localized only to the left ventricle. The present observation that the defect is expressed throughout skeletal muscle as well as cardiac lends further credence to the hypothesis that the phenotype of left ventricular septal hypertrophy is in part precipitated by the local environment in the left ventricle. Another explanation for the lack of skeletal muscle impairment may be compensation by other MHC isoforms present in the slow-twitch fibers such as skeletal muscle MHC. It is also possible that the fast-twitch fibers, which contain predominantly skeletal muscle MHC, may compensate for any abnormality in the slow-twitch fibers. Whether function is normal or impaired, the slow-twitch fibers would provide a much needed preparation for structure-function studies. Structure-function analysis of such a preparation obtained from a transgenic animal containing the mutated gene would yield insightful information relevant to the mechanism of contraction, not just the pathology of HCM.
Unraveling the molecular basis of how the putative mutant gene is responsible for the pathogenesis of the disease often requires years of investigation such as is now ongoing for Duchenne muscular dystrophy and cystic fibrosis. Studies must be pursued at both the mRNA and protein levels. Ultimate understanding will require knowledge of the protein and its in vivo specific functions. Furthermore, it is likely that ultimate elucidation at the molecular level of how f3-MHC mutations induce this disease will require expression of the mutation in a transgenic animal. The availability of skeletal muscle biopsies will make it possible to serially analyze for gene expression in such transgenic animals and assess the effect of mutation on skeletal and cardiac muscle functions. The finding of P-MHC expression in skeletal muscle minimizes one of the barriers to such investigations, i.e., inaccessibility of cardiac tissue. Skeletal muscle provides a convenient and easily accessible source of mRNA. Although a biopsy of skeletal muscle is not totally innocuous, it is a procedure that is performed routinely with almost no immediateor longterm deleterious effects. In contrast, it is much more difficult to obtain cardiac tissue. No attempt was made in this study to purify the protein product of the mRNA of either the normal or mutated allele, but this is a more accessible source than cardiac and adequate tissue can be obtained for protein isolation. It is of interest that while the autoradiogram of the PCR product does not lend itself to precise quantitative interpretation, the similar intensity of the normal and abnormal PCR product suggests there is equal expression of both the normal and the mutant allele. The intensity of the PCR product from the abnormal allele clearly indicates that the mutated allele is transcribed and the mRNA is processed to maturity and appropriately transported to the cytoplasm. It has been shown previously by Watkins et at9 and Rosenzweig et a130 that the P-MHC mRNA is also expressed in lymphocytes, as we have confirmed in this present study. Apart from the very low abundance of mRNA in lymphocytes requiring 75 cycles for amplification, the other limitation is the absence of the /3-MHC protein itself. It is unlikely that the 8-MHC protein is expressed to any extent in lymphocytes since this organ clearly does not require 13-MHC to perform its function. In contrast, 83-MHC is a major contractile protein of skeletal muscle analogous to that of cardiac muscle.
